DelveInsight added a report on “Chronic Spontaneous Urticaria Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Chronic Spontaneous Urticaria. The launch of emerging therapies will significantly impact the Chronic Spontaneous Urticaria market.
Chronic Spontaneous Urticaria Overview
Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or “wheals” on the skin. It is being associated with autoimmunity in almost half of the cases, but the remaining cases still remain “idiopathic,” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and is independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.
Get Sample Report @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market
Some of the key features of the Chronic Spontaneous Urticaria Market Report
- According to DelveInsight’s analysis, CSU is more prominent in females in comparison to males.
- The annual Chronic Spontaneous Urticaria prevalence rates over a 12-year period (2002-2013) were estimated, along with demographic and clinical determinants. The annual prevalence of CSU ranged from 0·02% in 2002 to 0·38% in 2013 in Italy.
- Chronic Spontaneous Urticaria companies such as Roche, Novartis, Sanofi Pharmaceutical, AstraZeneca, Kiniksa Pharmaceuticals Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company, and several others.
- Chronic Spontaneous Urticaria therapies such as XOLAIR, Dupilumab, Ligelizumab, Benralizumab, Fenebrutinib, and several others.
Chronic Spontaneous Urticaria Symptoms
- Raised or swollen welts on skin
- Itching
- Swelling
- Throat (angioedema)
Chronic Spontaneous Urticaria Pathophysiology
The pathophysiology of CSU is not well-understood, but it is clear that derangement of both mast cell and basophil activation and degranulation remains central to the process. Of these, mast cells are most widely accepted as the primary effectors of chronic urticaria. While other cell types, including lymphocytes and poly-mononuclear cells (PMNs), have been observed within the inflammatory infiltrates of patients with CSU.
Chronic Spontaneous Urticaria Diagnosis
A potential diagnostic pitfall is the failure to consider a diagnosis of urticarial vasculitis in patients with lesions lasting longer than 24 h, in patients with lesions associated with pain more than with itching, and in patients with lesions resolving with pigmentary changes or scaling. While in most cases, no diagnostic testing may be necessary, targeted laboratory testing based on clinical suspicion is appropriate. In most patients, the only screening tests that are recommended to be performed are a complete blood cell (CBC) count with differential, erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP), liver enzymes, and thyrotropin (TSH).
Chronic Spontaneous Urticaria Treatment
Several drugs have been implicated in the treatment of chronic urticaria with evidence ranging from randomized, double-blind placebo-controlled clinical investigations to anecdotal case reports. The newest guidelines recommend a stepwise approach to the pharmacological treatment of chronic urticaria. First-line therapy is nonsedating antihistamines, and if symptoms persist for more than 2 weeks, increasing doses up to fourfold the normal dose is recommended. If the symptoms persist for more than 4 weeks, the guidelines recommend the addition of omalizumab, cyclosporine A or montelukast (not in any preferred order). Other therapeutic options, which have not been included in the guideline, are dapsone, anticoagulants, methotrexate, azathioprine, mycophenolate mofetil, and biologics including intravenous immunoglobulins (IVIGs), rituximab, and adalimumab.
Get Sample Report @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market
Chronic Spontaneous Urticaria Epidemiology Segmentation
- Total Prevalent cases
- Age-specific cases
- Gender-Specific cases
- Total diagnosed and Treatable prevalent cases
Chronic Spontaneous Urticaria Treatment Market
The primary principle of treatment of CSU is to eliminate symptoms, including pruritus, wheals, and angioedema. H1-antihistamines function as inverse agonists that combine with and stabilize the inactive conformation of the H1-receptor. The treatment plan for chronic urticaria focuses on the treatment of the identifiable cause, avoidance of aggravating factors, and antihistamines trial. Topical lotions in the form of calamine lotion, menthol with aqueous cream, and crotamiton lotion are useful soothing agents in the treatment. There are few FDA approved therapies for the treatment of CSU.
Chronic Spontaneous Urticaria Market Insights
Several drugs have been implicated in the treatment of chronic urticaria with evidence ranging from randomized, double-blind placebo-controlled clinical investigations to anecdotal case reports. The newest guidelines recommend a stepwise approach to the pharmacological treatment of chronic urticaria. First-line therapy is nonsedating antihistamines, and if symptoms persist for more than 2 weeks, increasing doses up to fourfold the normal dose is recommended. If the symptoms persist for more than 4 weeks, the guidelines recommend the addition of omalizumab, cyclosporine A or montelukast (not in any preferred order).
Chronic Spontaneous Urticaria Emerging Therapies
- Dupilumab
- Ligelizumab
- Fenebrutinib
- MTPS9579A
Chronic Spontaneous Urticaria Emerging Therapy Assessment
The market has a promising outlook with many emerging therapies. Some of the major players in the global CSU market in the late phase of clinical development are Novartis {(Ligelizumab), (LOU064)}, Genentech (Fenebrutinib), Sanofi and Regeneron (Dupilumab), and others.
Chronic Spontaneous Urticaria Market Drivers
- Treatment Side Effects with Currently Available Treatment
- Economic Burden on Patients
- Increase in Research and Development Activities
- Increasing Market Size
Chronic Spontaneous Urticaria Market Barriers
- Lack of Understanding of Disease Pathology
- Approaching Patent Cliff
Request Sample Report @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market
Chronic Spontaneous Urticaria Market Report Scope
- Study Period- 2019-2032
- Coverage- The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
- Key Companies: Roche, Novartis, Sanofi Pharmaceutical, AstraZeneca, Kiniksa Pharmaceuticals Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company, and several others.
- Key Therapies: XOLAIR, Dupilumab, Ligelizumab, Benralizumab, Fenebrutinib, and several others.
- Unmet Needs
- KOL’s Views
- Market Drivers
- Market Barriers
Table of content
1. Key Insights
2. Executive Summary of Chronic Spontaneous Urticaria
3. Competitive Intelligence Analysis for Chronic Spontaneous Urticaria
4. Chronic Spontaneous Urticaria: Market Overview at a Glance
5. Chronic Spontaneous Urticaria: Disease Background and Overview
6. Patient Journey
7. Chronic Spontaneous Urticaria Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Spontaneous Urticaria Unmet Needs
10. Key Endpoints of Chronic Spontaneous Urticaria Treatment
11. Chronic Spontaneous Urticaria Marketed Products
12. Chronic Spontaneous Urticaria Emerging Therapies
13. Chronic Spontaneous Urticaria: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Chronic Spontaneous Urticaria
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/